Mirati Therapeutics MRTX shares are trading higher on Monday following positive preliminary data for MRTX849 for patients with advanced non-small cell lung cancer.
Mirati Therapeutics is an American biotechnology company. The company's medical focus is precision medicine: genetically targeted oncology therapeutics for selected patients. Mirati's drug candidates target specific genetic and epigenetic drivers of cancer.
Mirati Therapeutics shares traded up 13.97% to $205.36 on Monday at the time of publication. The stock has a 52-week high of $211.50 and a 52-week low of $66.01.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
